Evidence map›Paper›PMID 31413559›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2019

Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort.

Lan Ai Kieu Le, Ane Johannessen, Jon Andrew Hardie, Odd Erik Johansen, Amund Gulsvik, Bjørn Egil Vikse, Per Bakke

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Prognostic Properties of the GOLD 2023 Classification System.International journal of chronic obstructive pulmonary disease · 2023
    Article
  8. Article
  9. Article
  10. 2011 GOLD Stages of COPD: Transitions, Predictor Factors and Comparison with 2017 GOLD Stages.International journal of chronic obstructive pulmonary disease · 2020
    Article
  11. Article
  12. Prediction of Mortality Using Different COPD Risk Assessments - A 12-Year Follow-Up.International journal of chronic obstructive pulmonary disease
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lan Ai Kieu LeDepartment of Medicine, Haugesund Hospital, Haugesund, Norway.
Ane JohannessenDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Jon Andrew HardieDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Odd Erik JohansenDepartment of Medicine, Bærum Hospital, Gjettum, Norway.
Amund GulsvikDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Bjørn Egil VikseDepartment of Medicine, Haugesund Hospital, Haugesund, Norway.
Per BakkeDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 is based on an ABCD assessment tool of symptoms and exacerbation history and grade 1-4 of airflow limitation severity, facilitating classification either into 4 groups (ABCD) or 16 groups (1A-4D). We aimed to compare the GOLD 2011, GOLD 2017 ABCD, and GOLD 2017 1A-4D classifications in terms of their distribution and prediction of mortality and hospitalizations. Methods: In the GenKOLS study, 912 COPD patients with FEV1 less than 80% of the predicted answered questionnaires and performed lung function testing in 2003-2005. The patients were recruited from a hospital patient registry (n=662) and from the general population (n=250), followed up until 2011 with respect to all-cause and respiratory mortality, and all-cause and respiratory hospitalizations. We performed logistic regression and receiver operating curve (ROC) analyses for the different classifications with estimations of area under the curve (AUC) for comparisons. Results: Mean age at baseline was 60 years (SD 11), 55% were male. Mean duration of follow-up was 91 months. By GOLD 2011, 21% were classified as group A, 29% group B, 6% group C, and 43% as group D, corresponding percentages for GOLD 2017 were: 25%, 52%, 3%, and 20%. The GOLD 2011 classification had higher AUC values than the GOLD 2017 group ABCD classification for respiratory mortality and hospitalization, but after inclusion of airflow limitation severity in GOLD 2017 groups 2A-4D, AUC values were significantly higher with GOLD 2017. Conclusion: In a clinically relevant sample of COPD patients, the GOLD 2017 classification doubles the prevalence of group B and halves the prevalence of groups C and D as compared to the GOLD 2011 classification. The prediction of respiratory mortality and respiratory hospitalization was better for GOLD 2017 2A-4D taking airflow limitation severity into account, as compared to GOLD 2017 ABCD and GOLD 2011.

Indexed as

Pulmonary Disease, Chronic ObstructiveRespiratory Function TestsArea Under CurveClassificationDisease ProgressionFemaleHospitalizationHumansMaleMiddle AgedNorwayPrevalencePrognosisRegistriesSeverity of Illness IndexABCD classificationairflow limitationCox regressionhospitalizationmortalityrespiratory

Identifiers

PMID31413559
PMCPMC6662162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.